DC-TM4F2 Inhibitors belong to a specialized class of chemical compounds designed to target and interfere with the function of specific proteins or enzymes. These inhibitors are characterized by their selective affinity for the active or allosteric sites of their target molecules, allowing them to bind and induce conformational changes that reduce or abolish the protein's activity. The mechanism of inhibition typically involves the blockade of substrate access or interference with the protein's ability to undergo necessary conformational transitions that are essential for its biological function. DC-TM4F2 Inhibitors are often structurally complex, reflecting the intricate interactions they must form with their protein targets. The design of these molecules takes into account the shape, charge, and hydrophobic or hydrophilic properties of the target site to ensure a high degree of specificity and a strong binding affinity, reducing the likelihood of off-target effects.
The development and characterization of DC-TM4F2 Inhibitors require a deep understanding of the protein's structure and the dynamic processes it undergoes during its functional cycle. Advanced computational modeling, crystallography, and medicinal chemistry techniques play crucial roles in the creation of these inhibitors. Once identified, these compounds are subjected to rigorous in vitro assays to confirm their inhibitory activity and to determine the kinetics of their interactions with the protein target. These studies reveal not only the potency of the inhibitors but also provide insights into their mode of action at the molecular level. Such detailed information is essential for the subsequent optimization of the inhibitors, where chemical modifications are made to enhance their efficacy, selectivity, and stability, making them valuable tools for probing the protein's function within a biological context.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib targets the EGFR tyrosine kinase by competitive inhibition, which can reduce the activity of downstream signaling pathways such as PI3K/AKT that may be involved in the functional regulation of DC-TM4F2. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an inhibitor of the EGFR tyrosine kinase. Inhibition of this receptor leads to decreased activation of downstream pathways such as MAPK, which is implicated in the control of DC-TM4F2 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib acts as a multi-kinase inhibitor, targeting RAF kinases. Inhibition of RAF kinases disrupts the MAPK/ERK pathway, potentially downregulating the activity of DC-TM4F2 if it is regulated by this pathway. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases, including PDGFR and VEGFR. This blockade can reduce the phosphorylation cascades that may be essential for DC-TM4F2's functional expression or stability. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits the tyrosine kinase domains of both EGFR and HER2/neu, which may lead to reduced activation of signaling cascades that influence DC-TM4F2 activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib selectively inhibits BCR-ABL tyrosine kinase, c-Kit, and PDGFR. The inhibition of these kinases decreases activation of downstream signaling pathways that could govern the functional state of DC-TM4F2. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor affecting SRC family kinases. This inhibition could alter the phosphorylation status of proteins in pathways connected to DC-TM4F2 function. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib is a selective inhibitor of BCR-ABL tyrosine kinase, which could lead to modulated activity of downstream signaling affecting DC-TM4F2. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits VEGFR, EGFR, and RET tyrosine kinases. By inhibiting these receptors, it may decrease signaling processes that regulate DC-TM4F2 function. | ||||||